Concepts (269)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| NF-E2-Related Factor 2 | 15 | 2025 | 92 | 5.610 |
Why?
|
| Nitric Oxide Synthase Type I | 15 | 2022 | 57 | 4.470 |
Why?
|
| Nitric Oxide | 15 | 2025 | 386 | 4.260 |
Why?
|
| Gastroparesis | 9 | 2022 | 9 | 3.800 |
Why?
|
| Gastric Emptying | 10 | 2021 | 14 | 2.630 |
Why?
|
| Diabetes Mellitus, Experimental | 5 | 2022 | 131 | 2.340 |
Why?
|
| Porphyromonas gingivalis | 4 | 2024 | 40 | 1.690 |
Why?
|
| Acrolein | 3 | 2024 | 17 | 1.600 |
Why?
|
| Gastrointestinal Motility | 4 | 2019 | 20 | 1.400 |
Why?
|
| Saliva | 3 | 2023 | 119 | 1.340 |
Why?
|
| Periodontitis | 4 | 2026 | 62 | 1.310 |
Why?
|
| Periodontal Diseases | 4 | 2017 | 49 | 1.170 |
Why?
|
| Endothelium, Vascular | 6 | 2025 | 263 | 1.100 |
Why?
|
| Diabetes Complications | 3 | 2019 | 102 | 1.100 |
Why?
|
| Pylorus | 3 | 2018 | 4 | 1.040 |
Why?
|
| Pterins | 3 | 2018 | 4 | 1.000 |
Why?
|
| Antioxidants | 6 | 2021 | 443 | 0.920 |
Why?
|
| Stomach | 4 | 2019 | 50 | 0.900 |
Why?
|
| Animals | 35 | 2024 | 16992 | 0.820 |
Why?
|
| Mesenteric Arteries | 3 | 2015 | 20 | 0.820 |
Why?
|
| Estradiol | 7 | 2013 | 268 | 0.810 |
Why?
|
| Intestinal Mucosa | 1 | 2024 | 134 | 0.790 |
Why?
|
| Signal Transduction | 5 | 2025 | 2157 | 0.730 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2024 | 299 | 0.730 |
Why?
|
| Oxidative Stress | 6 | 2025 | 1003 | 0.720 |
Why?
|
| Mice | 15 | 2022 | 6644 | 0.700 |
Why?
|
| Mice, Knockout | 9 | 2022 | 1035 | 0.690 |
Why?
|
| Obesity | 2 | 2020 | 1151 | 0.690 |
Why?
|
| Maleimides | 1 | 2020 | 12 | 0.660 |
Why?
|
| Apolipoproteins E | 4 | 2015 | 138 | 0.660 |
Why?
|
| Mouth | 3 | 2017 | 54 | 0.640 |
Why?
|
| Hyperglycemia | 1 | 2020 | 61 | 0.620 |
Why?
|
| Pyloric Antrum | 3 | 2022 | 6 | 0.620 |
Why?
|
| MPTP Poisoning | 1 | 2019 | 12 | 0.610 |
Why?
|
| Calcitonin Gene-Related Peptide | 6 | 2013 | 11 | 0.590 |
Why?
|
| Indoles | 1 | 2020 | 187 | 0.580 |
Why?
|
| Bacteroidaceae Infections | 2 | 2015 | 7 | 0.570 |
Why?
|
| Cardiovascular Diseases | 2 | 2017 | 749 | 0.560 |
Why?
|
| Rats | 17 | 2024 | 3735 | 0.560 |
Why?
|
| Female | 29 | 2026 | 24698 | 0.550 |
Why?
|
| Diabetes Mellitus | 3 | 2018 | 539 | 0.520 |
Why?
|
| Muscle Relaxation | 5 | 2019 | 19 | 0.520 |
Why?
|
| Salivary Proteins and Peptides | 1 | 2016 | 5 | 0.480 |
Why?
|
| Xerostomia | 1 | 2016 | 3 | 0.480 |
Why?
|
| Mice, Inbred C57BL | 5 | 2020 | 1869 | 0.450 |
Why?
|
| Nitrergic Neurons | 2 | 2012 | 5 | 0.440 |
Why?
|
| Gastrointestinal Tract | 1 | 2015 | 71 | 0.430 |
Why?
|
| Gastric Mucosa | 2 | 2012 | 65 | 0.430 |
Why?
|
| Rats, Sprague-Dawley | 15 | 2016 | 1766 | 0.420 |
Why?
|
| Progesterone | 5 | 2013 | 121 | 0.400 |
Why?
|
| Reactive Oxygen Species | 3 | 2025 | 532 | 0.380 |
Why?
|
| Blotting, Western | 6 | 2019 | 883 | 0.380 |
Why?
|
| Estrogens | 2 | 2013 | 203 | 0.350 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 107 | 0.350 |
Why?
|
| Kidney Diseases | 1 | 2013 | 172 | 0.340 |
Why?
|
| Receptors, LDL | 1 | 2011 | 42 | 0.340 |
Why?
|
| Vitamin D | 1 | 2013 | 196 | 0.330 |
Why?
|
| Diabetic Neuropathies | 1 | 2010 | 12 | 0.330 |
Why?
|
| Gonadal Steroid Hormones | 4 | 2020 | 55 | 0.320 |
Why?
|
| Cytokines | 3 | 2024 | 678 | 0.320 |
Why?
|
| Sex Characteristics | 2 | 2011 | 258 | 0.310 |
Why?
|
| Humans | 17 | 2026 | 43102 | 0.300 |
Why?
|
| Hormones | 1 | 2009 | 55 | 0.290 |
Why?
|
| NG-Nitroarginine Methyl Ester | 5 | 2019 | 36 | 0.280 |
Why?
|
| Atherosclerosis | 3 | 2015 | 169 | 0.280 |
Why?
|
| Inflammation | 3 | 2025 | 758 | 0.250 |
Why?
|
| Colon | 2 | 2019 | 120 | 0.240 |
Why?
|
| Risk Factors | 6 | 2023 | 3994 | 0.240 |
Why?
|
| Oleanolic Acid | 1 | 2025 | 6 | 0.240 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2006 | 14 | 0.240 |
Why?
|
| Male | 19 | 2026 | 23409 | 0.230 |
Why?
|
| Disease Models, Animal | 5 | 2019 | 1596 | 0.230 |
Why?
|
| Flutamide | 1 | 2005 | 7 | 0.230 |
Why?
|
| Diet, Protein-Restricted | 1 | 2005 | 6 | 0.230 |
Why?
|
| Treponema denticola | 2 | 2015 | 5 | 0.220 |
Why?
|
| Aorta | 3 | 2015 | 198 | 0.220 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2015 | 28 | 0.210 |
Why?
|
| Sex Factors | 4 | 2013 | 1028 | 0.210 |
Why?
|
| Blood Glucose | 3 | 2011 | 389 | 0.210 |
Why?
|
| Aging | 2 | 2009 | 783 | 0.210 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2024 | 65 | 0.200 |
Why?
|
| RNA, Messenger | 4 | 2018 | 1271 | 0.200 |
Why?
|
| Gene Expression | 3 | 2021 | 701 | 0.200 |
Why?
|
| Membrane Proteins | 4 | 2019 | 561 | 0.200 |
Why?
|
| Dental Caries | 1 | 2024 | 57 | 0.190 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2016 | 75 | 0.190 |
Why?
|
| Pain | 1 | 2006 | 290 | 0.190 |
Why?
|
| Lipopolysaccharides | 1 | 2024 | 239 | 0.190 |
Why?
|
| Antihypertensive Agents | 1 | 2005 | 287 | 0.190 |
Why?
|
| Enzyme Inhibitors | 4 | 2019 | 458 | 0.180 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2022 | 29 | 0.180 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 3156 | 0.180 |
Why?
|
| Gene Expression Regulation | 3 | 2019 | 1070 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2020 | 760 | 0.180 |
Why?
|
| Superoxide Dismutase | 2 | 2012 | 158 | 0.170 |
Why?
|
| Epithelial Cells | 1 | 2024 | 434 | 0.170 |
Why?
|
| Cell Line | 1 | 2024 | 1410 | 0.160 |
Why?
|
| Down-Regulation | 2 | 2013 | 456 | 0.160 |
Why?
|
| Weight Gain | 1 | 2021 | 139 | 0.160 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2019 | 15 | 0.150 |
Why?
|
| Constipation | 1 | 2019 | 7 | 0.150 |
Why?
|
| Curcumin | 1 | 2021 | 118 | 0.150 |
Why?
|
| Heme Oxygenase-1 | 1 | 2019 | 52 | 0.150 |
Why?
|
| 1-Methyl-4-phenylpyridinium | 1 | 2019 | 28 | 0.150 |
Why?
|
| Vasodilation | 3 | 2010 | 64 | 0.150 |
Why?
|
| Parkinsonian Disorders | 1 | 2019 | 42 | 0.150 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2019 | 92 | 0.150 |
Why?
|
| alpha-Synuclein | 1 | 2019 | 61 | 0.150 |
Why?
|
| Body Weight | 2 | 2011 | 429 | 0.150 |
Why?
|
| Glucose | 1 | 2020 | 244 | 0.150 |
Why?
|
| Dimerization | 2 | 2010 | 112 | 0.150 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2019 | 105 | 0.140 |
Why?
|
| Insulin Resistance | 1 | 2020 | 201 | 0.140 |
Why?
|
| Vasomotor System | 2 | 2011 | 3 | 0.140 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2018 | 54 | 0.140 |
Why?
|
| Prevalence | 1 | 2023 | 1612 | 0.140 |
Why?
|
| Hypertension | 1 | 2005 | 835 | 0.140 |
Why?
|
| Apoptosis | 1 | 2025 | 1568 | 0.140 |
Why?
|
| Rats, Wistar | 1 | 2018 | 283 | 0.140 |
Why?
|
| Brain | 1 | 2006 | 1472 | 0.130 |
Why?
|
| Endothelial Cells | 1 | 2020 | 329 | 0.130 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 196 | 0.130 |
Why?
|
| Parkinson Disease | 1 | 2019 | 210 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 51 | 0.130 |
Why?
|
| Myositis | 2 | 2006 | 7 | 0.120 |
Why?
|
| Hyperalgesia | 2 | 2006 | 24 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 458 | 0.120 |
Why?
|
| Chronic Disease | 3 | 2015 | 549 | 0.120 |
Why?
|
| Fusobacterium nucleatum | 1 | 2015 | 9 | 0.110 |
Why?
|
| Biofilms | 1 | 2017 | 184 | 0.110 |
Why?
|
| Bacteroidetes | 1 | 2015 | 13 | 0.110 |
Why?
|
| alpha-Globins | 1 | 2014 | 4 | 0.110 |
Why?
|
| Adrenomedullin | 3 | 2010 | 4 | 0.110 |
Why?
|
| Gene Deletion | 1 | 2015 | 168 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2017 | 760 | 0.110 |
Why?
|
| Logistic Models | 1 | 2017 | 1009 | 0.110 |
Why?
|
| Placenta | 3 | 2004 | 117 | 0.100 |
Why?
|
| Crohn Disease | 1 | 2014 | 71 | 0.100 |
Why?
|
| Colitis, Ulcerative | 1 | 2014 | 70 | 0.100 |
Why?
|
| Ovariectomy | 3 | 2010 | 127 | 0.100 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2010 | 200 | 0.100 |
Why?
|
| Myocardial Contraction | 1 | 2013 | 46 | 0.100 |
Why?
|
| Cardiotonic Agents | 1 | 2013 | 40 | 0.100 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 1 | 2012 | 8 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2018 | 518 | 0.090 |
Why?
|
| Tissue Culture Techniques | 1 | 2012 | 36 | 0.090 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 223 | 0.090 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 48 | 0.090 |
Why?
|
| Random Allocation | 1 | 2012 | 147 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2012 | 575 | 0.090 |
Why?
|
| Peptide Fragments | 3 | 2013 | 307 | 0.090 |
Why?
|
| Receptors, Calcitonin | 2 | 2009 | 3 | 0.090 |
Why?
|
| Heart | 1 | 2013 | 184 | 0.090 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 2011 | 22 | 0.090 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2011 | 17 | 0.090 |
Why?
|
| Coronary Disease | 1 | 2012 | 123 | 0.080 |
Why?
|
| Peptides | 2 | 2005 | 372 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2017 | 719 | 0.080 |
Why?
|
| Pregnancy | 6 | 2010 | 1772 | 0.080 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2013 | 465 | 0.080 |
Why?
|
| Middle Aged | 4 | 2026 | 12222 | 0.080 |
Why?
|
| Uterine Artery | 1 | 2010 | 2 | 0.080 |
Why?
|
| Methotrexate | 1 | 2010 | 22 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 611 | 0.080 |
Why?
|
| Protein Structure, Quaternary | 1 | 2010 | 69 | 0.080 |
Why?
|
| Hypoxanthines | 1 | 2010 | 3 | 0.080 |
Why?
|
| Coronary Artery Disease | 1 | 2012 | 163 | 0.080 |
Why?
|
| Blood Pressure | 2 | 2005 | 666 | 0.080 |
Why?
|
| GTP Cyclohydrolase | 1 | 2010 | 5 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 94 | 0.080 |
Why?
|
| Trigeminal Ganglion | 2 | 2006 | 13 | 0.080 |
Why?
|
| Adult | 4 | 2026 | 13872 | 0.070 |
Why?
|
| Ganglia, Spinal | 1 | 2009 | 42 | 0.070 |
Why?
|
| Dietary Supplements | 1 | 2010 | 213 | 0.070 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2009 | 91 | 0.070 |
Why?
|
| Vasodilator Agents | 2 | 2010 | 55 | 0.070 |
Why?
|
| Tetrodotoxin | 1 | 2007 | 22 | 0.070 |
Why?
|
| Gestational Age | 2 | 2005 | 200 | 0.060 |
Why?
|
| Pressure | 1 | 2007 | 50 | 0.060 |
Why?
|
| Muscle, Smooth | 1 | 2007 | 58 | 0.060 |
Why?
|
| Muscle Contraction | 1 | 2007 | 67 | 0.060 |
Why?
|
| Electric Stimulation | 1 | 2007 | 186 | 0.060 |
Why?
|
| Neuropeptides | 1 | 2005 | 64 | 0.060 |
Why?
|
| Antibodies, Bacterial | 2 | 2015 | 117 | 0.050 |
Why?
|
| Oral Hygiene | 1 | 2024 | 23 | 0.050 |
Why?
|
| Fetus | 1 | 2004 | 101 | 0.050 |
Why?
|
| Beverages | 1 | 2024 | 66 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2026 | 719 | 0.050 |
Why?
|
| Oral Health | 1 | 2024 | 87 | 0.050 |
Why?
|
| Receptors, Calcitonin Gene-Related Peptide | 1 | 2002 | 2 | 0.050 |
Why?
|
| Fetal Growth Retardation | 1 | 2003 | 53 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2026 | 1081 | 0.050 |
Why?
|
| Cattle | 1 | 2024 | 498 | 0.050 |
Why?
|
| Pre-Eclampsia | 1 | 2003 | 67 | 0.050 |
Why?
|
| Fertility | 1 | 2002 | 62 | 0.040 |
Why?
|
| Animals, Newborn | 1 | 2002 | 352 | 0.040 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2002 | 192 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2026 | 2544 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 652 | 0.030 |
Why?
|
| Nitroglycerin | 1 | 1996 | 7 | 0.030 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 1996 | 21 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1996 | 42 | 0.030 |
Why?
|
| Gingival Diseases | 1 | 2015 | 3 | 0.030 |
Why?
|
| Child | 1 | 2024 | 3443 | 0.030 |
Why?
|
| Bone Density | 1 | 1996 | 103 | 0.030 |
Why?
|
| Serum Amyloid A Protein | 1 | 2015 | 14 | 0.030 |
Why?
|
| Alveolar Bone Loss | 1 | 2015 | 19 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2015 | 29 | 0.030 |
Why?
|
| Bacteremia | 1 | 2015 | 37 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2015 | 86 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2015 | 70 | 0.030 |
Why?
|
| Comet Assay | 1 | 2014 | 77 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 102 | 0.030 |
Why?
|
| Bone Resorption | 1 | 2014 | 22 | 0.030 |
Why?
|
| Gingivitis | 1 | 2014 | 9 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 58 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2010 | 1124 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 259 | 0.030 |
Why?
|
| Sarcomeres | 1 | 2013 | 8 | 0.030 |
Why?
|
| Behavior, Animal | 2 | 2006 | 373 | 0.020 |
Why?
|
| Cell Separation | 1 | 2013 | 94 | 0.020 |
Why?
|
| Tissue Distribution | 2 | 2004 | 240 | 0.020 |
Why?
|
| Litter Size | 2 | 2003 | 14 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 667 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2013 | 107 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2013 | 122 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2013 | 114 | 0.020 |
Why?
|
| DNA Damage | 1 | 2014 | 356 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 861 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 1067 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 287 | 0.020 |
Why?
|
| Cell Survival | 1 | 2014 | 945 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2013 | 183 | 0.020 |
Why?
|
| Glyburide | 1 | 2010 | 9 | 0.020 |
Why?
|
| Potassium Channel Blockers | 1 | 2010 | 35 | 0.020 |
Why?
|
| Aged | 2 | 2014 | 8214 | 0.020 |
Why?
|
| Calcium | 1 | 2013 | 491 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 2853 | 0.020 |
Why?
|
| Freund's Adjuvant | 1 | 2006 | 14 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2006 | 70 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2006 | 89 | 0.020 |
Why?
|
| Masseter Muscle | 1 | 2005 | 4 | 0.020 |
Why?
|
| Substance P | 1 | 2005 | 26 | 0.010 |
Why?
|
| Neurons, Afferent | 1 | 2005 | 44 | 0.010 |
Why?
|
| Afferent Pathways | 1 | 2005 | 43 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 934 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 5080 | 0.010 |
Why?
|
| Fetal Weight | 1 | 2003 | 9 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 536 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 6081 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 53 | 0.010 |
Why?
|
| Systole | 1 | 2003 | 67 | 0.010 |
Why?
|
| Labor, Obstetric | 1 | 2002 | 16 | 0.010 |
Why?
|
| Mifepristone | 1 | 2002 | 34 | 0.010 |
Why?
|
| Trophoblasts | 1 | 2002 | 33 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2002 | 196 | 0.010 |
Why?
|
| Growth | 1 | 2002 | 11 | 0.010 |
Why?
|
| Time Factors | 1 | 2006 | 1857 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2002 | 140 | 0.010 |
Why?
|
| Reference Values | 1 | 2002 | 211 | 0.010 |
Why?
|
| Birth Weight | 1 | 2002 | 95 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2005 | 1604 | 0.010 |
Why?
|
| United States | 1 | 2012 | 5205 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 306 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 1996 | 76 | 0.010 |
Why?
|
| Arginine | 1 | 1996 | 75 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 1996 | 135 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1996 | 234 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1996 | 195 | 0.010 |
Why?
|